PharmD Info

A forum for Indian Pharmacy Professionals

New to forum? Learn how to post your questions/topics --- Click Here
Its an inter-professional and collaborative learning platform for the doctors and other healthcare professionals to discuss on various healthcare issues and views with pharmacy professionals. Pharmacist also can assist and share your ideas for the better therapeutic outcomes based on clear evidence. E.g: Drug Information, Decision Analysis and EBM.
Forum rules: The contents of the, such as text, graphics, images, and other material contained on the Site ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Site!

If you think you may have a medical emergency, call your doctor or 108 immediately. does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site
  • User avatar
Researchers are beginning to explore whether the genetics of patients who experience a placebo effect are different from those of patients who don't. It's well known that people can feel better if they believe they are receiving treatment, but the biological pathways involved are relatively unexplored. In a new review, publishing in Trends in Molecular Medicine, scientists at Beth Israel Deaconess Medical Center discuss what we know as well as possible ethical issues related to conducting genetic tests to determine whether a patient is a placebo responder.
"Understanding the placebome - the collection of genes related to placebo responses - opens possibilities to improving patients' responses to clinical care and pharmaceuticals and to refining research designs for detecting drug-placebo differences," says lead author Kathryn Hall, PhD, a member of Beth Israel Deaconess Medical Center's Program in Placebo Studies.

Past studies have revealed that certain signaling pathways in the brain - especially the dopamine, opioid, endocannabinoid, and serotonin pathways - help mediate the placebo effect. Hall and her colleagues examined evidence that genetic variations in these pathways can modify the placebo effect; their findings raise the possibility of using genetic screens to identify placebo responders. Such information could lead to better patient selection for clinical trials - for example by pointing to those who should be excluded because they are likely to experience a benefit no matter what treatment they receive or by ensuring that potential placebo responders are evenly allocated across treatment arms.

Hall notes that if the placebo response is influenced by certain brain signaling pathways, then it might also affect patients' responses to drugs that target those same pathways, and the magnitude of the drug effect might differ from one patient to another as a result of their genotype.

"These are novel hypotheses that, to our knowledge, have not yet been discussed in the scientific literature," she says. "This broader conception that points to more personalized medicine calls for additional research." Her group proposes including no-treatment controls in addition to placebo controls in some future clinical trials. "Our proposal to incorporate a formal placebo study into future clinical trials is innovative and could represent significant cost savings, leading to rapid access to knowledge of mechanisms involved in the placebo response across a wide variety of disease and drug regimens," Hall says.

A number of ethical issues must be considered if genetic profiles of placebo responders can be established. If high placebo responders are not included in clinical trials, this raises several important questions. For example, how will the drugs be labeled, and which patients will be approved for treatment in light of the fact that the drugs will have only been tested in placebo non-responders? Should physicians test for genetic placebo-response propensities and should patients be allowed to refuse permission to be tested? Should patients be told about their propensity to respond to placebos, and could patients refuse to know or refuse to have this designation in their medical records? Would physicians be able to ethically use this information and, if so, how? And of course, what if knowing one is a placebo responder affects one's placebo response?

Source: ... ebo-effect
Similar Topics
Topics Statistics Last post
0 Replies 
by Admin
21 Dec 2017, 11:23
0 Replies 
by Admin
31 Jan 2018, 13:42
0 Replies 
by Admin
03 Feb 2017, 15:19
0 Replies 
by Admin
24 Jan 2018, 20:26
0 Replies 
by Admin
10 Aug 2017, 18:48


The word "prescription", derived[…]

Sir, Pay Scale ?

Course Name : Residency in Oncology Duration : […]

I take this opportunity to invite you to T.John C[…]